Yes, several epigenetic drugs have been approved for clinical use. For instance, Azacitidine and Decitabine are approved for the treatment of myelodysplastic syndromes. These drugs inhibit DNA methyltransferases, thereby reducing abnormal DNA methylation patterns frequently observed in cancer.
